Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.

Guarneri, Valentina; Dieci, Maria V; Griguolo, Gaia; Miglietta, Federica; Girardi, Fabio; Bisagni, Giancarlo; Generali, Daniele G; Cagossi, Katia; Sarti, Samanta; Frassoldati, Antonio; +9 more... Gianni, Lorenzo; Cavanna, Luigi; Pinotti, Graziella; Musolino, Antonino; Piacentini, Federico; Cinieri, Saverio; Prat, Aleix; Conte, PierFranco; of the CHER-Lob study team; CHER-Lob study team; (2021) Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European journal of cancer (Oxford, England : 1990), 153. pp. 133-141. ISSN 0959-8049 DOI: https://doi.org/10.1016/j.ejca.2021.05.018

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.ejca.2021.05.018

Abstract

Share

Download

Filename: 1-s2.0-S0959804921003270-main.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar